Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
Study Identifier:
NGLU-CL02
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: SBC-103
Date
Jan 2015 - Oct 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 12 Years
Requirements Information
Sex
Female & Male
Age
2 - 12 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: SBC-103
Date
Jan 2015 - Oct 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 12 Years years
Requirements Information
Protocol Summary
Study to evaluate the safety and tolerability of intravenous (IV) administration of SBC-103 in participants with mucopolysaccharidosis III, type B (MPS IIIB, Sanfilippo B) with evaluable signs or symptoms of developmental delay.
Trial Locations
Location
Status
Location
Minneapolis, Minnesota, United States, 55414
Status
N/A
Location
Pittsburgh, Pennsylvania, United States, 15224
Status
N/A
Location
Barcelona, Spain, 08950
Status
N/A
Location
Birmingham, United Kingdom, B4 6NH
Status
N/A